

JOURNAL OF CLINICAL ONCOLOGY

Official Journal of the American Society of Clinical Oncology

Vol 24, No 22

C O N T E N T S

August 1, 2006

Editorials

■ Cancer Survival: Time to Get Moving? Data Accumulate Suggesting a Link Between Physical Activity and Cancer Survival

Wendy Demark-Wahnefried (see articles on pages 3527 and 3535) 3517

Is the Fault in Our Steroids or in Our Selves?

Leslie R. Schover (see article on page 3576) 3519

■ Predicting Risk for the Appearance of Melanoma

Frank L. Meyskens Jr and David F. Ransohoff (see article on page 3590) 3522

Models Support Prophylactic Cranial Irradiation

Minesh P. Mehta (see article on page 3597) 3524

Original Reports

GASTROINTESTINAL CANCER

■ Physical Activity and Survival After Colorectal Cancer Diagnosis

Jeffrey A. Meyerhardt, Edward L. Giovannucci, Michelle D. Holmes, Andrew T. Chan, Jennifer A. Chan, Graham A. Colditz, and Charles S. Fuchs (see editorial on page 3517) 3527

■ ⓘ Impact of Physical Activity on Cancer Recurrence and Survival in Patients With Stage III Colon Cancer: Findings From CALGB 89803

Jeffrey A. Meyerhardt, Denise Heseltine, Donna Niedzwiecki, Donna Hollis, Leonard B. Saltz, Robert J. Mayer, James Thomas, Heidi Nelson, Renaud Whittom, Alexander Hantel, Richard L. Schilsky, and Charles S. Fuchs (see editorial on page 3517) 3535

Phase III Trial of Fluorouracil-Based Chemotherapy Regimens Plus Radiotherapy in Postoperative Adjuvant Rectal Cancer: GI INT 0144

Stephen R. Smalley, Jacqueline K. Benedetti, Stephen K. Williamson, John M. Robertson, Norman C. Estes, Tracy Maher, Barbara Fisher, Tyvin A. Rich, James A. Martenson, John W. Kugler, Al B. Benson III, Daniel G. Haller, Robert J. Mayer, James N. Atkins, Christine Cripps, John Pedersen, Phillip O. Periman, Michael S. Tanaka Jr, Cynthia G. Leichman, and John S. Macdonald 3542

(continued on following page)

Journal of Clinical Oncology (ISSN 0732-183X) is published 36 times a year, three times monthly, by American Society of Clinical Oncology, 1900 Duke St, Suite 200, Alexandria, VA 22314. Periodicals postage is paid at Alexandria, VA, and at additional mailing offices. Publication Mail Agreement Number 863289.

Editorial correspondence should be addressed to Daniel G. Haller, MD, *Journal of Clinical Oncology*, 330 John Carlyle St, Suite 300, Alexandria, VA 22314. Telephone: (703) 797-1900; Fax: (703) 684-8720. E-mail: jco@asco.org. Internet: www.jco.org.

POSTMASTER: ASCO members send change of address to American Society of Clinical Oncology, 1900 Duke St, Suite 200, Alexandria, VA 22314. Nonmembers send change of address to *Journal of Clinical Oncology* Customer Service, 330 John Carlyle St, Suite 300, Alexandria, VA 22314.

2006 annual subscription rates, effective September 1, 2005: United States and possessions: individual, \$435; single issue, \$35. International: individual, \$605; single issue, \$45. Institutions: Tier 1: \$615 US, \$870 Int'l; Tier 2: \$715 US, \$970 Int'l; Tier 3: \$1,035 US, \$1,290 Int'l; Tier 4: \$1,140 US, \$1,395 Int'l; Tier 5: contact *JCO* for a quote. See <http://www.jco.org/subscriptions/tieredpricing.shtml> for descriptions of each tier. Student and resident: United States and possessions: \$215; all other countries, \$300. To receive student/resident rate, orders must be accompanied by name of affiliated institution, date of term, and the signature of program/residency coordinator on institution letterhead. Orders will be billed at individual rate until proof of status is received. Current prices are in effect for back volumes and back issues. Back issues sold in conjunction with a subscription rate are on a prorated basis. Subscriptions are accepted on a 12-month basis. Prices are subject to change without notice. Single issues, both current and back, exist in limited quantities and are offered for sale subject to availability. *JCO* Legacy Archive (electronic back issues from January 1983 through December 1998) is also available; please inquire.

① Phase II Trial of Paclitaxel, Carboplatin, and Etoposide in Advanced Poorly Differentiated Neuroendocrine Carcinoma: A Minnie Pearl Cancer Research Network Study

John D. Hainsworth, David R. Spigel, Sharlene Litchy, and F. Anthony Greco 3548

Phase II Study of Recombinant Human Endostatin in Patients With Advanced Neuroendocrine Tumors

Matthew H. Kulke, Emily K. Bergsland, David P. Ryan, Peter C. Enzinger, Thomas J. Lynch, Andrew X. Zhu, Jeffrey A. Meyerhardt, John V. Heymach, William E. Fogler, Carolyn Sidor, Ann Michelini, Kate Kinsella, Alan P. Venook, and Charles S. Fuchs 3555

① Phase III Trial Comparing 4-Day Chronomodulated Therapy Versus 2-Day Conventional Delivery of Fluorouracil, Leucovorin, and Oxaliplatin As First-Line Chemotherapy of Metastatic Colorectal Cancer: The European Organisation for Research and Treatment of Cancer Chronotherapy Group

Sylvie Giacchetti, Georg Bjarnason, Carlo Garufi, Dominique Genet, Stefano Iacobelli, Marco Tampellini, Rune Smaaland, Christian Focan, Bruno Coudert, Yves Humblet, Jean Luc Canon, Antoine Adenis, Giovanni Lo Re, Carlos Carvalho, Johannes Schueller, Nicole Anciaux, Marie-Ange Lentz, Benoît Baron, Thierry Gorlia, and Francis Lévi 3562

Increasing Negative Lymph Node Count Is Independently Associated With Improved Long-Term Survival in Stage IIIB and IIIC Colon Cancer

Paul M. Johnson, Geoff A. Porter, Rocco Ricciardi, and Nancy N. Baxter 3570

SUPPORTIVE CARE AND QUALITY OF LIFE

The Impact of Hormone Replacement Therapy on Menopausal Symptoms in Younger High-Risk Women After Prophylactic Salpingo-Oophorectomy

Joanna B. Madalinska, Marc van Beurden, Eveline M.A. Bleiker, Heiddis B. Valdimarsdottir, Judith Hollenstein, Leon F. Massuger, Katja N. Gaarenstroom, Marian J.E. Mourits, René H.M. Verheijen, Eleonora B.L. van Dorst, Hans van der Putten, Ko van der Velden, Henk Boonstra, and Neil K. Aaronson (see editorial on page 3519) 3576

① Double-Blind, Placebo-Controlled Study of Quality of Life, Hematologic End Points, and Safety of Weekly Epoetin Alfa in Children With Cancer Receiving Myelosuppressive Chemotherapy

Bassem I. Razzouk, Jeffrey D. Hord, Marilyn Hockenberry, Pamela S. Hinds, James Feusner, Denise Williams, and Wayne R. Rackoff 3583

MELANOMA

① Identifying Individuals at High Risk of Melanoma: A Practical Predictor of Absolute Risk

Thomas R. Fears, DuPont Guerry IV, Ruth M. Pfeiffer, Richard W. Sagebiel, David E. Elder, Allan Halpern, Elizabeth A. Holly, Patricia Hartge, and Margaret A. Tucker (see editorial on page 3522) 3590

STATISTICAL/ECONOMIC ANALYSIS

① Decision Analysis for Prophylactic Cranial Irradiation for Patients With Small-Cell Lung Cancer

J. Jack Lee, B. Nebiyu Bekele, Xian Zhou, Scott B. Cantor, Ritsuko Komaki, and Jin Soo Lee (see editorial on page 3524) 3597

BONE MARROW TRANSPLANTATION

Risk Factors Before Autologous Stem-Cell Transplantation for Lymphoma Predict for Secondary Myelodysplasia and Acute Myelogenous Leukemia

Matt Kalaycio, Lisa Rybicki, Brad Pohlman, Ronald Sobecks, Steven Andresen, Elizabeth Kuczkowski, and Brian Bolwell 3604

BREAST CANCER

① Breast Cancer–Specific mRNA Transcripts Presence in Peripheral Blood After Adjuvant Chemotherapy Predicts Poor Survival Among High-Risk Breast Cancer Patients Treated With High-Dose Chemotherapy With Peripheral Blood Stem Cell Support

Miguel Quintela-Fandino, Joaquín Martínez López, Ricardo Hitt, Soledad Gamarra, Antonio Jimeno, Rosa Ayala, Javier Hornedo, Cecilia Guzman, Florinda Gilsanz, and Hernán Cortés-Funes 3611

Prospective Study of Incidence and Severity of Epiphora and Canalicular Stenosis in Patients With Metastatic Breast Cancer Receiving Docetaxel

Bitá Esmaeli, Sapna Amin, Vicente Valero, Rosnie Adinin, Rebecca Arbuckle, Roberto Banay, Kim-Anh Do, and Edgardo Rivera 3619

Randomized Phase II Trial of Letrozole and Letrozole Plus Low-Dose Metronomic Oral Cyclophosphamide As Primary Systemic Treatment in Elderly Breast Cancer Patients

Alberto Bottini, Daniele Generali, Maria Pia Brizzi, Stephen B. Fox, Alessandra Bersiga, Simone Bonardi, Giovanni Allevi, Sergio Aguggini, Giuliana Bodini, Manuela Milani, Rossana Dionisio, Claudio Bernardi, Arianna Montruccoli, Paolo Bruzzi, Adrian L. Harris, Luigi Dogliotti, and Alfredo Berruti 3623

■ Effect of Letrozole Versus Placebo on Bone Mineral Density in Women With Primary Breast Cancer Completing 5 or More Years of Adjuvant Tamoxifen: A Companion Study to NCIC CTG MA.17

Edith A. Perez, Robert G. Josse, Kathleen I. Pritchard, James N. Ingle, Silvana Martino, Brian P. Findlay, Tamara N. Shenkier, Richard G. Tozer, Michael J. Palmer, Lois E. Shepherd, Shifang Liu, Dongsheng Tu, and Paul E. Goss 3629

NEUROONCOLOGY

Health Status Measurements at Diagnosis As Predictors of Survival Among Adults With Brain Tumors

Helen McCarter, William Furlong, Anthony C. Whitton, David Feeny, Sonja DePauw, Andrew R. Willan, and Ronald D. Barr 3636

Phase I Single-Dose Study of Intracavitary-Administered Iodine-131-TM-601 in Adults With Recurrent High-Grade Glioma

Adam N. Mamelak, Steven Rosenfeld, Richard Bucholz, Andrew Raubitschek, L. Burt Nabors, John B. Fiveash, Sui Shen, M.B. Khazaeli, David Colcher, An Liu, Medhat Osman, Bart Guthrie, Susan Schade-Bijur, Diana M. Hablitz, Vernon L. Alvarez, and Matthew A. Gonda 3644

Phase II Trial of Tipifarnib in Patients With Recurrent Malignant Glioma Either Receiving or Not Receiving Enzyme-Inducing Antiepileptic Drugs: A North American Brain Tumor Consortium Study

Timothy F. Cloughesy, Patrick Y. Wen, H. Ian Robins, Susan M. Chang, Morris D. Groves, Karen L. Fink, Larry Junck, David Schiff, Lauren Abrey, Mark R. Gilbert, Frank Lieberman, John Kuhn, Lisa M. DeAngelis, Minesh Mehta, Jeff J. Raizer, W.K. Alfred Yung, Ken Aldape, John Wright, Kathleen R. Lamborn, and Michael D. Prados 3651

LUNG CANCER

① Phase III Study of Docetaxel Compared With Vinorelbine in Elderly Patients With Advanced Non–Small-Cell Lung Cancer: Results of the West Japan Thoracic Oncology Group Trial (WJTOG 9904)

Shinzoh Kudoh, Koji Takeda, Kazuhiko Nakagawa, Minoru Takada, Nobuyuki Katakami, Kaoru Matsui, Tetsu Shinkai, Toshiyuki Sawa, Isao Goto, Hiroshi Semba, Takashi Seto, Masahiko Ando, Taroh Satoh, Naruo Yoshimura, Shunichi Negoro, and Masahiro Fukuoka 3657

GENITOURINARY CANCER

① Prospective Study of *FGFR3* Mutations As a Prognostic Factor in Nonmuscle Invasive Urothelial Bladder Carcinomas

Silvia Hernández, Elena López-Knowles, Josep Lloreta, Manolis Kogevinas, Alex Amorós, Adonina Tardón, Alfredo Carrato, Consol Serra, Núria Malats, and Francisco X. Real 3664

GENETIC TESTING FOR CANCER

Clinical Characteristics Affect the Impact of an Uninformative DNA Test Result: The Course of Worry and Distress Experienced by Women Who Apply for Genetic Testing for Breast Cancer

Sandra van Dijk, Daniëlle R.M. Timmermans, Hanne Meijers-Heijboer, Aad Tibben, Christi J. van Asperen, and Wilma Otten 3672

PEDIATRIC ONCOLOGY

Phase I Study of Depsipeptide in Pediatric Patients With Refractory Solid Tumors: A Children's Oncology Group Report

Maryam Fouladi, Wayne L. Furman, Thomas Chin, Burgess B. Freeman III, Lorina Dudkin, Clinton F. Stewart, Mark D. Krailo, Roseanne Speights, Ashish M. Ingle, Peter J. Houghton, John Wright, Peter C. Adamson, and Susan M. Blaney 3678

① Residual Disease Monitoring in Childhood Acute Myeloid Leukemia by Multiparameter Flow Cytometry: The MRD-AML-BFM Study Group

Claudia Langebrake, Ursula Creutzig, Michael Dworzak, Ondrej Hrusak, Ester Mejstrikova, Frank Griesinger, Martin Zimmermann, and Dirk Reinhardt 3686

ASCO Special Article

■ American Society of Clinical Oncology Clinical Practice Guideline for the Use of Larynx-Preservation Strategies in the Treatment of Laryngeal Cancer

David G. Pfister, Scott A. Laurie, Gregory S. Weinstein, William M. Mendenhall, David J. Adelstein, K. Kian Ang, Gary L. Clayman, Susan G. Fisher, Arlene A. Forastiere, Louis B. Harrison, Jean-Louis Lefebvre, Nancy Leupold, Marcy A. List, Bernard O. O'Malley, Snehal Patel, Marshall R. Posner, Michael A. Schwartz, and Gregory T. Wolf 3693

Art of Oncology

The Bereavement Visit in Pediatric Oncology

Jerry Stein, Anat Peles-Borz, Ilana Buchval, Anat Klein, and Isaac Yaniv 3705

Correspondence

Polymorphism in the *CYP2D6* Tamoxifen-Metabolizing Gene Influences Clinical Effect but Not Hot Flashes: Data From the Italian Tamoxifen Trial

Bernardo Bonanni, Debora Macis, Patrick Maisonneuve, Harriet A. Johansson, Giacomo Gucciardo, Pasquale Oliviero, Roberto Travaglini, Maria G. Muraca, Nicole Rotmensz, Umberto Veronesi, and Andrea U. Decensi 3708

In Reply

Matthew P. Goetz, James M. Rae, Stephanie L. Safgren, Matthew M. Ames, Daniel W. Visscher, Carol Reynolds, Fergus Couch, Wilma L. Lingle, David A. Flockhart, Zeruesenay Desta, Edith A. Perez, and James N. Ingle 3709

Relapse Pattern of GOG 122 Trial Should Be More Informative

Enis Ozyar and Mine Genc 3709

In Reply

Marcus E. Randall and Virginia L. Filiaci 3710

Family Physician Versus Specialist Care for Breast Cancer Follow-Up

Ellen Warner and Judith Weinroth 3710

The Oncology Nurse Practitioner: A Unique Provider for the Follow-Up for Early-Stage Breast Cancer

Margaret Q. Rosenzweig 3710

In Reply

Eva Grunfeld, Mark N. Levine, and Jim A. Julian 3711

Sentinel Lymph Node Sampling and Analysis in Colon Cancer: What Is the Question?

Marc Pocard, Marc Van den Eynde, Diane Goere, Valérie Boige, and David Malka 3712

In Reply

Mark Redston and Monica M. Bertagnolli 3713

Radiation Therapy for Aggressive Fibromatosis (desmoid tumor)

Michael E. Ray and Theodore S. Lawrence 3714

In Reply

George D. Demetri and Michael C. Heinrich 3715

Erratum 3716

Also in This Issue

Announcements

Information for Contributors

Current Abstracts

Calendar of Oncology Events



Online supplementary information available at www.jco.org



Article was published online ahead of print at www.jco.org